Prognosis of Binet stage A chronic lymphocytic leukemia patients: The strength of routine parameters

Blood

Volumn 116, Issue 22, 2010, Pages 4588-4590

  Letestu, Rémi ^a,b,c   Lévy, Vincent ^c,d   Eclache, Virginie ^a,b,c   Baran Marszak, Fanny ^a,b,c   Vaur, Dominique ^e   Naguib, Dina ^e   Schischmanoff, Olivier ^a,b,c   Katsahian, Sandrine ^d   Nguyen Khac, Florence ^f   Davi, Frédéric ^f   Merle Béral, Hélène ^f   Troussard, Xavier ^e   Ajchenbaum Cymbalista, Florence ^a,b,c  

^a UNIVERSITÉ PARIS 13   (France)

^b INSERM   (France)

^c AVICENNE HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CHU CÔTE DE NACRE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; HUMAN; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STANFORD-BINET INTELLIGENCE SCALE;

EID: 78649455942     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-288274     Document Type: Article

References (21)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2): 219-234.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206.
3. Hamblin TJ. Prognostic markers in chronic lympocytic leukaemia. Best Pract Res Clin Haematol. 2007;20(3):455-468.
4. Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23(1): 25-47.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
6. Deglesne PA, Chevallier N, Letestu R, et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res. 2006;66(14):7158-7166.
7. Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37(Database issue):D1006-D1012.
8. Le Garff-Tavernier M, Ticchioni M, Brissard M, et al. National standardization of ZAP-70 determination by flow cytometry: the French experience. Cytometry B Clin Cytom. 2007;72(2):103-108.
9. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable- region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-1775.
10. Letestu R, Rawstron A, Ghia P, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry B Clin Cytom. 2006;70(4):309-314.
11. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679-4685.
12. Molica S, Mauro FR, Callea V, et al. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMAexperience. Haematologica. 2010;95(3): 464-469.
13. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115(2):363-372.
14. Del Giudice I, Morilla A, Osuji N, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer. 2005; 104(10):2124-2132.
15. Weinberg JB, Volkheimer AD, Chen Y, et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol. 82(12):1063-1070.
16. D'Arena G, Tarnani M, Rumi C, et al. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol. 2007;82(9):787-791.
17. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901.
18. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.
19. Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol. 2003;56(5):441-447.
20. Vlad A, Deglesne PA, Letestu R, et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res. 2009;69(16):6387-6395.
21. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008; 112(5):1923-1930.